Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

1.

The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.

Nestal de Moraes G, Souza PS, Costas FC, Vasconcelos FC, Reis FR, Maia RC.

Leuk Res Treatment. 2012;2012:671702. doi: 10.1155/2012/671702. Epub 2012 Apr 24.

PMID:
23259070
[PubMed]
Free PMC Article
2.

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS.

Leuk Res. 2010 Oct;34(10):1255-68. doi: 10.1016/j.leukres.2010.04.016. Review.

PMID:
20537386
[PubMed - indexed for MEDLINE]
3.

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.

Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J.

Mol Cancer. 2010 May 19;9:112. doi: 10.1186/1476-4598-9-112.

PMID:
20482842
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.

Baran Y, Saydam G.

J Blood Med. 2012;3:139-50. doi: 10.2147/JBM.S29132. Epub 2012 Nov 16.

PMID:
23180974
[PubMed]
Free PMC Article
5.

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

Li S.

Leuk Lymphoma. 2008 Jan;49(1):19-26. doi: 10.1080/10428190701713689. Review.

PMID:
18203007
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Epub 2005 Oct 5. Review.

PMID:
16213151
[PubMed - indexed for MEDLINE]
7.

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.

Oncogene. 2002 Dec 12;21(57):8804-16.

PMID:
12483533
[PubMed - indexed for MEDLINE]
Free Article
8.

Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.

Nambu T, Araki N, Nakagawa A, Kuniyasu A, Kawaguchi T, Hamada A, Saito H.

Cancer Sci. 2010 Jan;101(1):137-42. doi: 10.1111/j.1349-7006.2009.01365.x. Epub 2009 Sep 14.

PMID:
19843070
[PubMed - indexed for MEDLINE]
9.

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.

von Bubnoff N, Peschel C, Duyster J.

Leukemia. 2003 May;17(5):829-38. Review.

PMID:
12750693
[PubMed - indexed for MEDLINE]
10.

Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.

Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, Taniwaki M.

Mol Cancer Res. 2010 Jul;8(7):994-1001. doi: 10.1158/1541-7786.MCR-10-0040. Epub 2010 Jun 22.

PMID:
20571063
[PubMed - indexed for MEDLINE]
Free Article
11.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

PMID:
18577747
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.

Sattler M, Salgia R.

Cytokine Growth Factor Rev. 1997 Mar;8(1):63-79. Review.

PMID:
9174663
[PubMed - indexed for MEDLINE]
13.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD.

Adv Exp Med Biol. 2003;532:121-40. Review.

PMID:
12908554
[PubMed - indexed for MEDLINE]
14.

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J.

Ann Intern Med. 2006 Dec 19;145(12):913-23. Review.

PMID:
17179059
[PubMed - indexed for MEDLINE]
15.

BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.

Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A, von Eggeling F.

Int J Oncol. 2011 Sep;39(3):585-91. doi: 10.3892/ijo.2011.1062. Epub 2011 Jun 1.

PMID:
21637917
[PubMed - indexed for MEDLINE]
16.

Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors.

Daley GQ.

Semin Hematol. 2003 Apr;40(2 Suppl 2):11-4. Review.

PMID:
12783369
[PubMed - indexed for MEDLINE]
17.

[Nilotinib as a second-line treatment for chronic myeloid leukemia].

Yamauchi T, Ueda T.

Gan To Kagaku Ryoho. 2011 Jun;38(6):911-5. Japanese.

PMID:
21677481
[PubMed - indexed for MEDLINE]
18.

Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Swords R, Alvarado Y, Giles F.

Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S113-9. Review.

PMID:
17382020
[PubMed - indexed for MEDLINE]
19.

Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Sawyers CL.

Semin Hematol. 2001 Jul;38(3 Suppl 8):15-21. Review.

PMID:
11526597
[PubMed - indexed for MEDLINE]
20.

Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.

Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O.

Oncogene. 2007 May 10;26(21):2975-87. Epub 2006 Nov 27.

PMID:
17130834
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk